A Phase II Open-Label Study of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC)
Latest Information Update: 21 Apr 2025
At a glance
- Drugs Enfortumab vedotin (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms EPIC
- 16 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 20 Jan 2024 Trial design, presented at the 2024 Gastrointestinal Cancers Symposium
- 26 Jun 2023 New trial record